The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.
about
Targeted therapy for advanced renal cell carcinomaTargeted therapy for advanced renal cell carcinomaThe Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathwaySetting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer TherapiesShortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model).Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.Development of growth inhibitory agents in urological and other malignancies.Speeding up the evaluation of new agents in cancer.Estimation of renal cell carcinoma treatment effects from disease progression modelingApplications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.Anti-Obesity Agents and the US Food and Drug Administration.The impact of molecular targets in cancer drug development: major hurdles and future strategies.Impact of molecular targets in cancer drug development: historical influence and future perspectives.Ethics, error, and initial trials of efficacyThe changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer as well.Novelty without toxicity: a quest for a safer local anesthetic.Molecular prescreening to select patient population in early clinical trials
P2860
Q24242946-6A60DE23-BFD0-472A-B4E6-1149DD32608AQ24244090-D0403D59-1CE7-4BD2-A37E-A2AAFD030815Q28476288-C8932972-2860-4FD1-922B-BFAFB140991DQ31097586-DEA124B6-4DE6-437F-851F-93597C47E14AQ33985780-FA09FEEA-9DA0-4FB7-8D17-78039316631AQ34193514-334F7415-5942-4E93-B5A7-F613EA4BFCE5Q35584926-7083F710-AFEB-42CE-8BA0-52EAA0198A03Q36145455-90C8703A-DBC4-498C-9092-603031152ED3Q36157118-4DB5E910-5A81-45CE-AB26-A62B3315B3BCQ36303184-03272C87-D439-4E77-BEE5-F25767AF76E7Q36530430-1412BBE0-AF5F-46AA-B5EC-F3FA2FAA7E91Q36858876-3E716DDF-0D3F-4AAD-B0CB-A8ABDC765796Q37217573-C7E5D2D7-6207-4CF8-8E1A-6F31EDBC0725Q38193714-B8D6C0CF-4E82-4F75-9D2E-CFE6085B3928Q38655569-2D0D498F-8049-484B-A1F5-983A821CD442Q39494507-2B0AEA1F-0BA1-4DEE-9318-6F73F8663C6FQ39897053-AF7BC638-7F16-472A-ADB4-B4BBF2BA92EFQ42395017-C0EDC375-7A7E-494A-ADCA-570DDDE976BEQ43421550-0909B64B-579B-4FBB-8D48-59536506FD8CQ46079920-8AE9E59C-0608-47CD-A8C1-27DB5000DBA9Q46581102-226DFF89-5C5E-413A-9B75-D8F40F853C01Q48314866-8AE72943-0751-444F-BCDA-EA8C9D920936Q58614572-923C4B1D-F09D-48BF-8BC1-7B2FD39D3E25
P2860
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The phase III trial in the era ...... ng the "go or no go" decision.
@ast
The phase III trial in the era ...... ng the "go or no go" decision.
@en
type
label
The phase III trial in the era ...... ng the "go or no go" decision.
@ast
The phase III trial in the era ...... ng the "go or no go" decision.
@en
prefLabel
The phase III trial in the era ...... ng the "go or no go" decision.
@ast
The phase III trial in the era ...... ng the "go or no go" decision.
@en
P2093
P356
P1476
The phase III trial in the era ...... ng the "go or no go" decision.
@en
P2093
Bruce A Chabner
Thomas G Roberts
Thomas J Lynch
P304
P356
10.1200/JCO.2003.01.204
P407
P577
2003-10-01T00:00:00Z